After trimming an early-stage Crohn’s disease candidate from its pipeline this year, Takeda is dealing with the failure of another of its therapies in a related indication. Alofisel (daradstrocel), a ...

- Data on Patients with Complex Crohn’s Perianal Fistulas Were Presented at the European Crohn’s and Colitis Organisation (ECCO) 2022 Congress 1 - INSPIRE is the First Observational, Multicenter, Post ...

Please provide your email address to receive an email when new articles are posted on . Takeda Pharmaceuticals announced that it has enrolled the first patient in its registry established to gather ...

Takeda has chalked up a big win this week after receiving a European licence for Alofisel (darvadstrocel), marking the first approved allogeneic stem cell therapy set to hit the EU market. Alofisel – ...

Takeda has chalked up another milestone for its Alofisel cell therapy for a complication of Crohn's disease, becoming the first allogeneic stem cell therapy to be approved in Japan. Alofisel ...

(RTTNews) - Takeda Pharmaceutical Co. Ltd. (TAK), said on Friday that clinical remission was observed in 65% of patients with Crohn's disease and complex perianal fistulas in a phase III trial, dubbed ...

OSAKA, Japan & CAMBRIDGE, Mass. — Takeda (TSE:4502/NYSE: TAK) today announced that the Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel ® (darvadstrocel) for the treatment of ...

Japan’s Ministry of Health, Labour and Welfare approved Takeda Pharmaceutical Co. Ltd.’s Alofisel (darvadstrocel) to treat complex perianal fistulas in patients with non-active or mildly active ...

TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) and Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced that the European Commission (EC) has approved Alofisel ...

“Complex perianal fistulas are a painful, disabling and often embarrassing complication of Crohn’s disease that can be extremely challenging to treat. 9,10,11,12 Despite advances, many patients ...

Japan’s Ministry of Health, Labour and Welfare approved Takeda Pharmaceutical Co. Ltd.’s Alofisel (darvadstrocel) to treat complex perianal fistulas in patients with non-active or mildly active ...

- First allogeneic stem cell therapy to receive central marketing authorization approval in Europe - Alofisel offers a new treatment option for patients who do not respond to current available ...